Evaluation of Approved Antivirals for Inhibition of Xenotropic Murine Leukemia-Related Virus (XMRV) in Cell-Based Assays (ScienceDirect)
Ik zal niet alles kopieren en plakken, want de studie is niet vrij toegankelijk, maar dit stuk is interessant:
"Twenty-eight drugs approved for use in humans were evaluated against XMRV replication in vitro."
en
"An in vitro assay utilizing PG-4 cells infected with XMRV collected from 22Rv1 human prostate cancer cells was developed to measure inhibition of virus replication. Efficacy and toxicity data for the approved antiviral agents will be reported, as well as evaluation of combined antiviral agents in the anti-XMRV assay."
Oftewel we kunnen binnenkort een studie verwachten naar het effect van een groot aantal antivirale middelen op XMRV. Helaas staat er niet bij wanneer precies.
Studie naar effect antivirale middelen op XMRV
Moderator: Moderators
-
magnetronnie
- Gevorderd lid
- Berichten: 536
- Lid geworden op: 27 nov 2010, 10:15
-
magnetronnie
- Gevorderd lid
- Berichten: 536
- Lid geworden op: 27 nov 2010, 10:15
Studie naar effect antivirale middelen op XMRV
Wat voor antivirale middelen nemen jullie trouwens? Nexavir heb ik al gehoord, of is dat nog niet specifiek voor XMRV?
Is DML de enige arts in België en Nederland op dit moment die antivirale middelen voorschrijft?
Is DML de enige arts in België en Nederland op dit moment die antivirale middelen voorschrijft?
Studie naar effect antivirale middelen op XMRV
Interessant, ben zeer benieuwd ! Ik neem zelf inderdaad Nexavir maar ook GcMAF.. maar of dat een anti viraal middel is specifiek... wordt wel toegepast bij mensen met HIV onder andere..
As If I could reach Rainbows..
And if you want a rainbow you have to put up with the rain..
And if you want a rainbow you have to put up with the rain..
Studie naar effect antivirale middelen op XMRV
Geen van beide is een anti viraal middel...
Studie naar effect antivirale middelen op XMRV
Wat raar, ik lees hier toch echt:error schreef:Geen van beide is een anti viraal middel...
'Nexavir is een breed antiviraal middel dat eveneens immuunversterkend werkt. Nexavir behoort tot de antivirale geneesmiddelen(..)'
As If I could reach Rainbows..
And if you want a rainbow you have to put up with the rain..
And if you want a rainbow you have to put up with the rain..
Studie naar effect antivirale middelen op XMRV
Nexavir (Kutapressin)
Is a prescription drug produced from pig liver that is believed to have anti-inflammatory and anti-viral properties. Favorable responses to NEXAVIR® in patients with skin diseases (acne vulgaris, herpes zoster, "poison ivy" dermatitis, pityriasis rosea, seborrheic dermatitis, urticaria and eczema) and severe sunburn have been reported. One study suggested in-vitro effectiveness against the HHV-6 virus.
bron: http://www.kutapressin.com/
'is believed' Dus mijns inziens staat dit nog steeds niet vast.
Is a prescription drug produced from pig liver that is believed to have anti-inflammatory and anti-viral properties. Favorable responses to NEXAVIR® in patients with skin diseases (acne vulgaris, herpes zoster, "poison ivy" dermatitis, pityriasis rosea, seborrheic dermatitis, urticaria and eczema) and severe sunburn have been reported. One study suggested in-vitro effectiveness against the HHV-6 virus.
bron: http://www.kutapressin.com/
'is believed' Dus mijns inziens staat dit nog steeds niet vast.
Studie naar effect antivirale middelen op XMRV
Oh vandaar ik begrijp wat je bedoeld. Maar dat betekent nog niet dat het geen anti viraal middel is, het wordt al sinds 1940? gebruikt tegen verschillende virussen, als het niet zou werken dan zou het ook niet meer ingezet worden tegen virussen en dus niet meer bestaan.
Ik ben dan wel erg benieuwd of Nexavir betrokken is bij deze studie
Ik ben dan wel erg benieuwd of Nexavir betrokken is bij deze studie
As If I could reach Rainbows..
And if you want a rainbow you have to put up with the rain..
And if you want a rainbow you have to put up with the rain..
Studie naar effect antivirale middelen op XMRV
Laten we het houden op 'niet erkend' anti-viraal dan
Anders zouden we het hier in Belgie op voorschrift kunnen verkrijgen...
En is deze studie niet dezelfde als dit? http://www.me-gids.net/module-ME_CVS_do ... d-522.html
Anders zouden we het hier in Belgie op voorschrift kunnen verkrijgen...
En is deze studie niet dezelfde als dit? http://www.me-gids.net/module-ME_CVS_do ... d-522.html
Misschien voor de mensen op het forum die minder vertrouwd zijn met het Engels;
het gaat hier om studies in celculturen, niet in mensen.
Daarbij zijn er al dergelijke studies gedaan (waarbij er een paar Hiv middelen bleken te werken), dus dit is in feite niet zo nieuw.
Abstract
BACKGROUND:
XMRV (xenotropic murine leukemia virus-related virus) is the first known example of an exogenous gammaretrovirus that can infect humans. A limited number of reports suggest that XMRV is intrinsically resistant to many of the antiretroviral drugs used to treat HIV-1 infection, but is sensitive to a small subset of these inhibitors. In the present study, we used a novel marker transfer assay to directly compare the antiviral drug sensitivities of XMRV and HIV-1 under identical conditions in the same host cell type.
RESULTS:
We extend the findings of previous studies by showing that, in addition to AZT and tenofovir, XMRV and HIV-1 are equally sensitive to AZddA (3'-azido-2',3'-dideoxyadenosine), AZddG (3'-azido-2',3'-dideoxyguanosine) and adefovir. These results indicate that specific 3'-azido or acyclic nucleoside analog inhibitors of HIV-1 reverse transcriptase (RT) also block XMRV infection with comparable efficacy in vitro. Our data confirm that XMRV is highly resistant to the non-nucleoside RT inhibitors nevirapine and efavirenz and to inhibitors of HIV-1 protease. In addition, we show that the integrase inhibitors raltegravir and elvitegravir are active against XMRV, with EC50 values in the nanomolar range.
CONCLUSIONS:
Our analysis demonstrates that XMRV exhibits a distinct pattern of nucleoside analog susceptibility that correlates with the structure of the pseudosugar moiety and that XMRV is sensitive to a broader range of antiretroviral drugs than has previously been reported. We suggest that the divergent drug sensitivity profiles of XMRV and HIV-1 are partially explained by specific amino acid differences in their respective protease, RT and integrase sequences. Our data provide a basis for choosing specific antiretroviral drugs for clinical studies in XMRV-infected patients.
het gaat hier om studies in celculturen, niet in mensen.
Daarbij zijn er al dergelijke studies gedaan (waarbij er een paar Hiv middelen bleken te werken), dus dit is in feite niet zo nieuw.
Abstract
BACKGROUND:
XMRV (xenotropic murine leukemia virus-related virus) is the first known example of an exogenous gammaretrovirus that can infect humans. A limited number of reports suggest that XMRV is intrinsically resistant to many of the antiretroviral drugs used to treat HIV-1 infection, but is sensitive to a small subset of these inhibitors. In the present study, we used a novel marker transfer assay to directly compare the antiviral drug sensitivities of XMRV and HIV-1 under identical conditions in the same host cell type.
RESULTS:
We extend the findings of previous studies by showing that, in addition to AZT and tenofovir, XMRV and HIV-1 are equally sensitive to AZddA (3'-azido-2',3'-dideoxyadenosine), AZddG (3'-azido-2',3'-dideoxyguanosine) and adefovir. These results indicate that specific 3'-azido or acyclic nucleoside analog inhibitors of HIV-1 reverse transcriptase (RT) also block XMRV infection with comparable efficacy in vitro. Our data confirm that XMRV is highly resistant to the non-nucleoside RT inhibitors nevirapine and efavirenz and to inhibitors of HIV-1 protease. In addition, we show that the integrase inhibitors raltegravir and elvitegravir are active against XMRV, with EC50 values in the nanomolar range.
CONCLUSIONS:
Our analysis demonstrates that XMRV exhibits a distinct pattern of nucleoside analog susceptibility that correlates with the structure of the pseudosugar moiety and that XMRV is sensitive to a broader range of antiretroviral drugs than has previously been reported. We suggest that the divergent drug sensitivity profiles of XMRV and HIV-1 are partially explained by specific amino acid differences in their respective protease, RT and integrase sequences. Our data provide a basis for choosing specific antiretroviral drugs for clinical studies in XMRV-infected patients.